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Abstract
AIM
To investigate whether circulating cytokeratin-positive 
(CK+) cells in the mesenteric blood of resected colorectal 
specimens are prognostic and correlate with tumor 
budding.
METHODS
Fifty-six colorectal specimens were collected between 
9/2007 and 7/2008. Blood from the mesenteric vein 
was drawn immediately after receiving the fresh and 
unfixed specimens in the pathology department. After 
separation of the mononuclear cells by Ficoll-Hypaque 
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density-gradient centrifugation, cytological smears were 
immunocytochemically stained for CK18. Tumor budding 
was evaluated on slides stained for pan-cytokeratin. The 
identification of ≥ 30 buds/1.3 mm2 was defined as high 
grade budding.
RESULTS
CK+ cells and clusters were identified in 29 (48%) and 
14 (25%) of the samples, respectively. Two cells were 
identified in one of three non-malignant cases. Clusters 
were found exclusively in malignant cases. The occurrence 
of CK+ cells or clusters was not associated with any of the 
evaluated clinicopathological factors, including surgical 
technique and tumor budding. Moreover, the occurrence 
of CK+ cells or clusters had no influence on the cancer-
specific survival [75 mo (CI: 61; 88) vs  83 mo (CI: 72; 
95) and 80 mo (CI: 63; 98) vs  79 mo (CI: 69; 89), 
respectively].
CONCLUSION
CK+ cells and showed neither prognostic significance 
nor an association with tumor budding. It is very likely 
that CK18-staining is not specific enough to identify the 
relevant cells. 
Key words: Colorectal cancer; Circulating cells; Tumor 
budding; Peripheral blood; Survival
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Core tip: Blood from the mesenteric vein of 56 colorectal 
specimens was drawn and evaluated for CK18 positive 
epithelial cells (CK+). CK+ cells and clusters were identified 
in a high proportion of cases. However, these cells and 
clusters were not associated with any of the evaluated 
clinicopathological factors, including surgical technique 
and tumor budding. Moreover, the occurrence of CK+ 
cells or clusters had no influence on the cancer specific 
survival. Immunocytochemical staining for CK18 does not 
seem to be a specific marker of mesenteric blood cells for 
prognostic identification of relevant circulating tumor cells.
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INTRODUCTION
Colorectal cancer is a leading cause of cancer-related death, 
with almost 50000 estimated deaths in the United States 
in 2016[1]. The prognosis and therapy strongly depend 
on the UICC tumor stage. Nevertheless, it is well known 
that a certain proportion of stage Ⅰ/Ⅱ cancers develop an 
aggressive clinical course. However, approximately 40% 
of stage Ⅲ cancers show a favorable outcome despite the 
occurrence of regional lymph node (LN) metastases[2]. 
Therefore, alternative or additional prognostic factors 
are necessary to improve both prognostic estimation 
and therapeutic stratification in colorectal cancer. The 
National Comprehensive Cancer Network (NCCN) defined 
risk factors in stage Ⅱ colorectal cancers that justify the 
administration of an adjuvant therapy[3]. Several attempts 
have been made to identify other staging strategies. A very 
sophisticated approach is the development of multigene 
assays that could be demonstrated to be prognostic 
in stage Ⅱ colorectal cancers[4,5]. However, due to the 
limited evidence concerning their clinical value, these 
tests were not recommended by the NCCN. The only 
molecular feature that garnered a recommendation is the 
microsatellite instability (MSI) status[3]. Very recently, MSI, 
which is caused by mismatch repair (MMR) deficiency, was 
demonstrated to be highly predictive for immunotherapy 
by PD-1 blockade[6,7] Since 2005, Pagès et al[8] focused on 
the host’s immune response to the tumor. They developed 
an immune score based on the densities of CD3+ and 
CD8+ T-cells and showed that this score is independently 
prognostic. Currently, a large international multicenter 
study is ongoing to validate the prognostic role of the 
immunoscore[9]. A different approach is the detection, 
quantification and analysis of circulating tumor cells (CTC). 
These cells circulate in the blood stream or are found in the 
bone marrow and are believed to be a source of distant 
metastases. Based on our experiences handling and 
cannulating fresh colorectal specimens[10,11] for LN isolation, 
we hypothesized that the detection of epithelial cells in the 
venous blood of these specimens could be prognostic for 
the development of hematogenous tumor dissemination 
and progressive disease. Furthermore, we were interested 
in whether the occurrence of circulating CK+ cells is 
associated with tumor budding. Therefore, we collected 
blood samples from these specimens and evaluated the 
occurrence of cytokeratin-positive (CK+) cells. In this 
retrospective study we analyzed the prognostic role of 
these cells in colorectal cancer.
MATERIALS AND METHODS
Patients
Fifty-six colorectal cancer cases were collected between 
September 2007 and July 2008. We assumed a strong 
correlation between the detection of circulating CK+ 
cells and the occurrence of distant metastases with 
lethal outcome. An absolute difference concerning 
lethal outcome of 50% with a power of 0.8 and with 
Alpha = 0.05 resulted in a calculated sample size of 
19 cases in each group (proportions sample size test). 
Inclusion criteria were proven or suspected cancer, 
a curative intent and free resection margins. For the 
survival analysis, only malignant cases with a minimal 
survival time of 2 mo were included. Follow-up data were 
provided by the Clinical and Population-Based Cancer 
Registry of Augsburg. Additional data were acquired from 
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clinical and laboratory information systems. Informed 
and written consent was obtained from all patients. The 
study was approved by the ethics committee of the 
Landesärztekammer Bayern. The study was performed 
according to the national rules.
Blood sample collection 
Immediately after resection, colorectal specimens were 
delivered fresh to the in-house laboratory of the Institute 
of Pathology. The specimens were not opened to avoid 
contamination by epithelial cells from the mucosa. Manual 
manipulation was reduced to a minimum to reduce the 
chance of artificial tumor dissemination. After gentle 
cleaning, the specimens were placed on a clean board 
and the main vessels were clamped proximally. Then, the 
ligation or the clip that was placed by the surgeon was 
withdrawn. The venous vessel was then cannulated with 
a standard i.v.-catheter (17 Gauge, Braun, Melsungen, 
Germany). Zero point five milliliter to 8 mL (mean: 3.8 
mL; SD: 2.6 mL) of venous blood was drawn using NH4-
heparin blood collection tubes (Sarstedt, Nürnbrecht, 
Germany) (Figure 1). Then, the blood sample was 
immediately stored until future use.
Blood sample preparation and immunocytochemistry
The protocol for preparing the cytological samples was 
initially established for the detection of CK+ cells in bone 
marrow aspirates[12,13]. In brief, the mononuclear cells 
were separated by Ficoll-Hypaque density gradient cen-
trifugation (density, 1.077 g/mole) at 900 × g for 30 
min. The cells were then washed and centrifuged at 150 
× g for 5 min. Approximately 1 × 106 cells were placed 
on each glass slide. 
To detect epithelial cells within the peripheral blood, a 
monoclonal antibody against cytokeratin 18 [Clone CK18 
(Clone CK2), 1: 100; Chemicon, Hofheim, Germany] 
was used. The reactions were developed with the alkaline 
phosphatase anti-alkaline phosphatase technique com-
bined with a new fuchsin stain to indicate antibody 
binding, as previously described[12,13]. CK+ cells and 
clusters were counted manually (Figure 2). For that all 
slides were screened by a very experienced technician. 
All positive cases were confirmed by a hemato-oncologist 
(DO). Data concerning interobserver agreement between 
these two investigators are not available.
Histopathological evaluation, immunohistochemistry 
and tumor budding
Colorectal specimens were macroscopically evaluated 
after fixing overnight in 10% buffered formalin. LNs 
were dissected using the methylene-blue method[10,11]; 
samples from the resection margins, the tumor-region 
and other conspicuous areas were paraffin-embedded. 
The slides were stained with hematoxylin and eosin (HE) 
and evaluated by an experienced pathologist (BM). Based 
on the HE-morphology, slides were selected for further 
pan-cytokeratin staining which was performed to enable 
optimal evaluation of tumor budding. For this evaluation, 
monoclonal mouse antibody AE1/AE3 was used (dilution 
1:50; DAKO). Immunoreactions were developed using a 
labelled streptavidin-biotin system (DAKO Real detection 
system). All reactions were performed on a Dako-Auto-
stainer system (DAKO, Glostrup, Denmark).
Tumor budding was evaluated by one pathologist 
(BM). It was defined as detached single tumor cells or 
clusters of up to four cells. The cut-off for high-grade 
budding was adapted from Ueno et al[14] and defined as 
≥ 30 buds/20 × magnification (= 1.3 mm²).
Statistical analysis
Metric data were compared using the Mann-Whitney 
rank sum test. Tabulated data were analyzed with the 
Figure 1  This image illustrates the blood draw from the mesenteric vein. 
A standard i.v. catheter is used to cannulate the mesenteric vein after removal 
of the clip. 
Figure 2  Cytokeratin 18 (Clone cytokeratin 2) cytochemistry. A: A single 
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χ 2 test or Fisher’s exact test depending on the expected 
frequency of the observations. Mean values are given 
± 1 standard deviation (SD). Linear regression analysis 
was performed to calculate correlations between metric 
data. For the survival analyses, Kaplan-Meier curves 
were calculated and log-rank tests were performed. ROC 
analyses were performed to determine the optimized 
cut-offs. The calculation of the follow-up time was 
performed according to Schemper and Smith[15]. A P value 
< 0.05 was considered significant. All calculations were 
performed using the statistics package SigmaPlot 13.0 
(Systat, Richmond, VA, United States). The statistical 
methods of this study were reviewed by Bruno Märkl.
RESULTS
Patients 
Fifty-six patients were consecutively collected within 10 
mo between 2007 and 2008. The patient characteristics 
are summarized in Table 1. The mean and median follow-
up times were 74 (95%CI: 68; 79 mo) and 80 mo (CI: 
77; 83 mo), respectively.
CK+ cells and clusters and their relation to 
clinicopathological characteristics
CK+ cells were found in 29 (52%) cases with a mean 
number of 12 ± 14 cells/106 cells. One of these cases 
was non-malignant with two detected CK+ cells. CK+ cell 
clusters were detected in 14 (25%) cases. The mean 
number of clusters in positive cases was 3 ± 3 clusters/106 
cells. No clusters were found in non-malignant cases 
(Figure 2). There was a strong correlation between CK+ 
cells and clusters (R = 0.727; P < 0.001). Clusters were 
always accompanied with single CK+ cells.
None of the evaluated clinicopathological features 
(age, gender, location, LN count, grading, T-stage, meta-
stases) showed an association with the occurrence of 
CK+ cells or clusters (Table 1). In particular, neither CK+ 
cells nor CK+ clusters showed an association with tumor 
budding (R = 0.180; P = 0.185 and R = 0.0637; P = 
0.647, respectively). The surgical technique (open vs 
laparoscopic technique) did not influence the occurrence 
of CK+ cells or clusters (Table 1).
Survival analysis
Forty-eight cases met the inclusion criteria for the 
cancer-specific survival (CSS) analysis. The CSS analysis 
revealed no significant differences between cases with or 
without CK+ cells or clusters (Figure 3A and B). Despite 
the lack of significance, the Kaplan-Meier curve for CK+ 
cells discriminated between CK+ positive and negative 
cases with mean CSS times of 75 mo (CI: 61; 88) vs 83 
mo (CI: 72; 95) (Figure 3A), respectively. The outcome 
of CK+ cluster positive and negative cases was identical, 
with mean survival times of 80 mo (CI: 63; 98) vs 79 mo 
(CI: 69; 89) (Figure 3B), respectively. A non-significant 
trend towards an adverse outcome was found in cases 
with high-grade tumor budding, with a mean survival 
time of 71 mo (CI: 53; 89 mo) vs 83 mo (CI: 73; 93 
mo) (P = 0.187, Figure 3C), respectively. ROC analysis 
identified a certain cut-off that was not positive, i.e., did 
not reveal a threshold with areas under the curve of 0.51 
and 0.55 for CK+ cells and clusters, respectively.
DISCUSSION
In this study, we investigated the prognostic role of 
circulating CK+ cells and clusters obtained from the 
mesenteric blood of colorectal specimens. It was our 
hypothesis that the venous blood from these specimens 
should be enriched in circulating CK+ positive cells 
originating from the tumor. We used a technique that was 
well established for the detection of CK+ cells in the bone 
marrow of breast, prostate, lung and colorectal cancer 
Table 1  Clinicopathological data
Complete collective 
n  = 56
CK+ cell negative 
n  = 27
CK+ cell 
positive n  = 29
P-value CK+ cell cluster 
negative n  = 42 
CK+ cell cluster 
positive n  = 14
P-value
Mean age ± SD 70 ± 13 71 ± 11 69 ± 11 0.844 71 ± 12 66 ± 13 0.167
Gender (M:F) 1:1.5 1:1.7 1:1.4 1.0 1:2 1:0.75 0.538
Laparoscopic surgery 15 (27%) 5 (19%) 10 (34%) 10 (24%) 5 (36%)
Open surgery 41 (73%) 22 (81%) 19 (66%) 0.223 32 (76%) 9 (64%) 0.489
Right colon 21 (38%) 10 (37%) 11 (38%) 16 (38%) 5 (36%)
Left colon 29 (52%) 13 (48%) 16 (55%) 0.927 21 (50%) 8 (57%) 0.979
Rectum 6 (11%) 4 (15%) 2 (7%) 0.4141 5 (12%) 1 (7%) 1.0a
Mean LN count ± SD 32 ± 19 29 ± 16 35 ± 21 0.219 30 ± 16 36 ± 25 0.961
LN positivity 20 (36%) 11 (41%) 9 (31%) 0.632 16 (38%) 4 (29%) 0.747
Low grade 33 (59%) 17 (63%) 22 (76%) 28 (67%) 11 (79%)
High grade 20 (36%) 8 (30%) 6 (21%) 0.576 11 (26%) 3 (21%) 0.735
Non-malignant 3 (5%) 2 (7%) 1 (3%) n.c. 3 (7%) 0 (0%) n.c.
pT1/2 16 (29%) 7 (26%) 9 (31%) 11 (26%) 5 (36%)
pT3/4 37 (66%) 18 (67%) 19 (66%) 0.977 28 (67%) 9 (64%) 0.736
Mean budding ± SD 21 ± 27 20 ± 23 22 ± 30 0.957 19 ± 20 21 ± 26 0.663
High grade budding 16 (29%) 6 (22%) 10 (34%) 0.472 10 (24%) 6 (43%) 0.190
Distant metastases 11 (20%) 5 (19%) 6 (21%) 1.0 8 (19%) 3 (21%) 1.0
1Rectum vs colon. CK+: Cytokeratin positive; SD: Standard deviation; LN: Lymph node; n.c.: Not calculated.
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patients. Using this method, the detection of cytokeratin-
positive cells in the bone marrow could be demonstrated 
to be prognostic[12,13,16,17]. 
In this study, we found circulating CK+ cells and 
clusters in the mesenteric blood in a high proportion of 
cases (52% and 27%, respectively). This positive rate 
is within the range published in the literature (Table 1). 
However, it must be noted that only Leather et al[18] used 
immunocytochemistry to detect circulating epithelial cells 
in the mesenteric blood. In all other identified studies, 
molecular or flow cytometry techniques were used[19-35]. 
By using case numbers, we calculated a mean positivity 
rate in these studies of 43%. When we restricted 
this calculation to studies that also included stage Ⅳ 
cases, the mean positivity rate was 55%. We detected 
2 CK+ cells/106 cells in one non-malignant case with 
diverticulitis. The phenomenon of circulating epithelial 
cells in the blood in the absence of a malignant tumor 
has been found by other authors. Pantel et al[36] reported 
the detection of CK+ cells in benign colon diseases using 
two different commercial tests in 11.3% and 18.9% of 
cases, respectively. In summary, this indicates that the 
results generated with our immunocytochemical method 
are comparable to other techniques and are valid.
Despite using an obviously sensitive method, we 
could not confirm our hypothesis of circulating epithelial 
cells in the mesenteric blood being prognostic markers 
of colorectal cancer that correlate with tumor budding. 
This study is limited by a relatively small case number (n 
= 56) and is therefore underpowered to detect effects 
that are possibly smaller than expected. We presumed 
that the prognostic effect of CK+ cells was at least as 
strong as node positivity. Indeed, nodal status revealed 
a good discrimination with regards to cancer specific 
survival with a P value of 0.058 (data not shown). The 
strengths of this study are the long follow-up time and 
the precise evaluation of histological features including an 
immunohistochemical tumor budding assessment. 
Tumor budding is a well investigated prognostic para-
meter in gastrointestinal cancers. Despite considerable 
limitations due to the lack of a generally accepted definition 
and only moderate interobserver agreement, it has 
been shown in many studies[37,38]. It is believed to be an 
expression of the epithelial-mesenchymal transition (EMT), 
which is an important initial step in cancer progression[39]. 
None of the studies shown in Table 2 investigated the 
possible relationship between the phenomenon of tumor 
cell isolation at the invasion front of colorectal cancers and 
cCK+ negative
cCK+ positive
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Table 2  Literature: Circulating tumor cells in the mesenteric blood
the occurrence of CTCs in the blood. Moreover, a literature 
search within the Medline, Embase and Google Scholar 
databases did not reveal an investigation that addressed 
this topic. Cao et al[40] postulated in a review that EMT leads 
to tumor budding and subsequent blood vessel invasion. 
However, this is not supported by other references. To us, 
it seemed quite obvious that a correlation between these 
two factors exists. However, we were not able to confirm 
this hypothesis. We could not identify a correlation between 
tumor budding and circulating CK+ cells and could not 
confirm that a combination of tumor budding and CK+ cells 
was prognostic. Tumor budding alone discriminated clearly 
between two prognostic groups (Figure 3C). However, 
significance was likely not achieved due to the small sample 
number. 
The data concerning the prognostic significance 
of CTCs and disseminated tumor cells (DTCs) are con-
flicting[41]. However, there is growing evidence that CTC/
DTCs are of prognostic significance. Two commercial tests 
based on immunomagnetic separation targeting EpCAM 
(BerEp4) are currently available. They have proven to be 
prognostic, particularly in the metastatic stage of different 
cancers including colorectal cancer[42,43]. Two meta-
analyses addressed this topic. Katsuno et al[44] restricted 
their analysis to molecularly detected CTCs in mesenteric 
blood and included 9 studies. They found a favorable 
outcome in patients negative for CTCs [hazard ratio (HR) 
0.4-0.08][44]. Rahbari et al[45] included 36 studies with 
a total 3094 patients. They also identified a prognostic 
effect of CTCs. However, stratification according to the 
sampling compartment revealed that CTCs of peripheral 
blood were prognostic but those of the mesenteric bone 
marrow blood were not[45]. Similarly, our study found that 
the identification of CK+ cells or clusters had no prognostic 
effect. In addition, the approach using ROC analyses to 
identify a certain cut-off of cells which might be prognostic 
failed. 
CTCs seem to comprise different cell types of neo-
plastic and non-neoplastic origin. Moreover, it is very 
likely that cells derived from cancer have different 
potential to escape from immunogenic destruction and 
to establish tumor growth at a distant site. Depending 
on the compartment, cells may undergo a change in 
their phenotype[40,41,46]. As mentioned before, EMT is a 
hallmark process in cancer progression and is associated 
with impaired outcome[46,47]. Cells undergoing EMT 
lose their epithelial phenotype and gain mesenchymal 
features. The use of methods optimized for the detection 
of epithelial cells is prone to fail in the detection of all 
CTCs. Moreover, these methods may fail to detect the 
most relevant cells[48]. Currently, the most interesting 
cells in this context are cells with stem-cell features. The 
realization of a fast, exact and cost effective technical 
method to detect these cells is likely the most promising 
approach. 
In this study, we hypothesized that the immuno-
cytochemical detection of CK+ cell in the mesenteric 
blood of colorectal cancer specimens correlates with 
tumor budding and could serve as an easy to determine 
prognostic factor. Drawing the blood after resection would 
avoid delay and additional risk during the operation. None 
of these hypotheses could be confirmed in our study. Given 
the current literature, peripheral blood and not mesenteric 
blood is the optimal material for the detection of CTCs. More 
sophisticated techniques including molecular approaches 
are relatively expensive and their availability is limited. 
Nevertheless, they have the potential to detect exactly 
the cells which are most likely to be relevant to the clinical 
Ref. n Year Method Material Stages %positive Prognostic relevance
Leather et al[18] 42 1993 ICC Mesenteric and peripheral blood Ⅰ, Ⅱ, Ⅲ, Ⅳ 15 n.a.
Nakamori et al[19] 35 1997 PCR Mesenteric and peripheral blood Ⅰ, Ⅱ, Ⅲ, Ⅳ 26 uv predictive for recurrence
Luo et al[20] 54 1999 PCR Mesenteric blood Ⅰ, Ⅱ, Ⅲ, Ⅳ 76 Predictive for metastases
Taniguchi et al[22] 53 2000 PCR Mesenteric and peripheral blood Ⅰ, Ⅱ, Ⅲ 68 uv survival
Yamaguchi et al[23] 52 2000 PCR Mesenteric blood Ⅰ, Ⅱ, Ⅲ, Ⅳ 44 mv survival
Iinuma et al[21] 23 2000 MACS Mesenteric blood Ⅰ, Ⅱ, Ⅲ, Ⅳ 39 uv survival
Fujita et al[25] 35 2001 PCR Mesenteric blood Ⅰ, Ⅱ, Ⅲ 29 uv recurrence/survival
Etoh et al[24] 24 2001 PCR Mesenteric blood Ⅰ, Ⅱ, Ⅲ, Ⅳ 29 uv recurrence/survival
Guller et al[26] 39 2002 PCR Mesenteric and peripheral blood Ⅰ, Ⅱ, Ⅲ 81/282 3
Tien et al[27] 58 2002 PCR Mesenteric and peripheral blood Ⅱ, Ⅲ, Ⅳ 454 n.a.
Akashi et al[28] 80 2003 PCR Mesenteric blood Ⅰ, Ⅱ, Ⅲ 44 uv metastatic disease; mv no
Nozawa et al[29] 41 2003 RTA Mesenteric and peripheral blood Ⅰ, Ⅱ, Ⅲ, Ⅳ 37 uv predictive for metastatic disease
Sunouchi et al[30] 37 2003 PCR Mesenteric blood Ⅰ, Ⅱ, Ⅲ, Ⅳ 43 uv survival
Zhang et al[32] 58 2005 PCR Bone marrow, portal blood, 
peripheral blood
Ⅰ, Ⅱ, Ⅲ, Ⅳ 74 correlation with stage - no outcome analysis
Sadahiro et al[31] 100 2005 PCR Mesenteric and peripheral blood Ⅰ, Ⅱ, Ⅲ 455/486 no
Kanellos et al[34] 108 2006 PCR Mesenteric blood Ⅰ, Ⅱ, Ⅲ 11 uv metastatic disease/survival
Iinuma et al[33] 167 2006 PCR Mesenteric and peripheral blood Ⅰ, Ⅱ, Ⅲ, Ⅳ 10/347 mv survival
Tseng et al[35] 135 2015 FACS Mesenteric Ⅰ, Ⅱ, Ⅲ 68 mv survival
1Blood; 2Blood and peritoneal fluid; 3No separate evaluation for blood samples; 4Multiple measurements; 5Mesenteric blood; 6Peripheral blood; 7Mesenteric. 
n.a.: Not available; uv: Uni-variable; mv: Multi-variable; ICC: Immunocytochemistry; PCR: Polymerase chain reaction; MACS: Magnetic activated cell 
sorting; FACS: Fluorescence activated cell sorting.
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course of the disease. Immunocytochemical detection 
seems to be less specific and is not favorable.
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Background
Colorectal cancer is one of the most common cancers in men and women. Its 
prognosis depends mainly on the (UICC-) tumor stage. However, it is also known 
that certain proportion of cancers with otherwise favorable features and low 
stages show an aggressive clinical course while locally advanced cancers so not 
relapse. It is accepted that the detection of circulating tumor cells has the potential 
to improve the prognosis estimation not only in colorectal cancer.
Research frontiers
The main topic in the research field of circulating tumor cells is the influence of 
the different compartments (peripheral blood, mesenteric blood or bone marrow) 
on the clinical significance of the detected cells. Other important questions are 
the methods for the assessment and the type of cells (e.g., stem cells) which are 
most informative to predict the outcome.
Innovations and breakthroughs 
The innovation of this study is the evaluation of the blood draw from resected 
specimens. A direct correlation with tumor budding as a source for the circulating 
tumor cells is also a new approach. 
Applications 
Because the authors’ hypotheses could not be confirmed, the main conclusions 
are that mesenteric blood is probably not the best compartment for the 
identification of the relevant cells and more sophisticated methods may be 
superior over immunocytochemistry. Molecular techniques are more sensitive in 
detecting cells with a high potential to serve as the origin for distant metastases. 
Terminology
Circulating tumor cells are cells that lost its cohesion to the primary tumor mass 
and achieved access to the vascular system including the bone marrow. 
Peer-review
This is an interesting manuscript which appears to add to the existing body of 
literature around this subject. The design is clear.
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